Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

NVS 75.54 -0.38 (-0.50%)
price chart
Institutional Move From SEC: Quest Investment Management INC Lowered Novartis ...
Quest Investment Management Inc decreased its stake in Novartis A G Sponsored Adr (NVS) by 19.84% based on its latest 2016Q2 regulatory filing with the SEC.
Novartis AG (ADR) 19.3% Potential Upside Now Implied by Chardan Capital Markets
Novartis AG (ADR) using SYMBOL/TICKER code NYSE:NVS has had its stock rating noted as 'Reiterated' with the recommendation being set at 'BUY' yesterday by research analysts at Chardan Capital Markets.
Novartis AG (ADR) (NVS) Q3 Earnings: What Leerink Expects
Leerink's 2016 EPS estimate for Novartis stands at $4.8 on revenue of $50.5 billion, compared to consensus of $4.7 and $49 billion, respectively.
Institutional Heat: Cambridge Trust Company Upped Novartis Ag Sponsored Adr ...
Cambridge Trust Company increased its stake in Novartis Ag Sponsored Adr (NVS) by 76.95% based on its latest 2016Q2 regulatory filing with the SEC.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words
How do you mix medicine and photography? That's what Novartis AG (ADR) (NYSE:NVS) is doing and it feels nothing strange about it.
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data  Insider Monkey (blog)
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration  TCC
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
Novartis AG (NYSE:NVS) To Spend $100 Million On Expansion Of French mAb Plant  Market Exclusive
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen?  Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy  Bidness ETC
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Market Runner: Novartis AG (ADR) Has Another Very Weak Trading Session
They expect $1.19 EPS, down 6.30% or $0.08 from last year's $1.27 per share. NVS's profit will be $3.08 billion for 15.82 P/E if the $1.19 EPS becomes a reality.